Koers Propanc Biopharma Inc Other OTC
Aandelen
US74346N1072
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 559K 512K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -2 mln. -1,83 mln. | Nettowinst (verlies) 2023 | -2 mln. -1,83 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 1,09 mln. 1 mln. | Nettoschuld 2023 | 536K 492K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-0,07
x | K/w-verhouding 2023 |
-0,08
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,78% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 15-10-07 | |
Julian Kenyon
FOU | Founder | 77 | 15-10-07 |
Klaus Kutz
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 15-10-07 | |
Julian Kenyon
FOU | Founder | 77 | 15-10-07 |
Josef Zelinger
BRD | Director/Board Member | 74 | 23-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |